You are here:


AOP Orphan Contact

AOP Orphan worldwide

Wilhelminenstraße 91/IIf
1160 Vienna, Austria
office(at)aoporphan.com

Cooperation Opportunities


Using the filter below you can find products potentially available for out-licensing in specific countries, including current regulatory status. You are welcome to express your interest by sending a message to our dedicated team at partnering(at)aoporphan.com.

Belgium
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Cyprus
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: Dosier available
Greece
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Ireland
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Italy
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Luxembourg
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: Dosier available
Malta
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Netherlands
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Portugal
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Spain
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Canada
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Mexico
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
USA
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: Dosier available
Kazakhstan
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: approved
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Russia
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Ukraine
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved